Tecnoglass to Attend the Raymond James 45th Annual Institutional Investors Conference
Miami, FL, March 04, 2024 (GLOBE NEWSWIRE) — Tecnoglass, Inc. (NYSE: TGLS) (“Tecnoglass” or the “Company”), a leading producer of high-end aluminum […]
TSX News -
Probe Gold Announces Acquisition of the Beaufor and McKenzie Break Properties in Val-d’Or, Quebec
Highlights: The Beaufor Property is within the Company’s Novador property boundaries and currently hosts a high-grade, measured and indicated gold […]
TSX News -
Monarch Sells Mining Assets to Probe Gold and Bullrun
MONTREAL, March 04, 2024 (GLOBE NEWSWIRE) — MONARCH MINING CORPORATION (“Monarch” or the “Corporation”) (TSX: GBAR) announces that it has entered […]
Madison Metals Returns 2.78% U3O8 Over 4 Metres From Trench Sampling at Khan Project in Namibia, Africa
TORONTO, March 04, 2024 (GLOBE NEWSWIRE) — Madison Metals Inc. (“Madison” or the “Company”) (CSE: GREN) (OTCQB: MMTLF) (FSE: 4EF0) […]
iRhythm Announces Proposed Offering of $450.0 Million of Convertible Senior Notes
SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (“iRhythm”) (NASDAQ:IRTC), a leading digital health care company focused […]
TC Energy announces sale of Portland Natural Gas Transmission System
Generates pre-tax cash equity proceeds of approximately $740 million (US$545 million) net to TC Energy Transaction implies a valuation multiple […]
Healthcare Realty Trust Announces Planned Retirement of Two Directors and 2024 Nominees
NASHVILLE, Tenn., March 04, 2024 (GLOBE NEWSWIRE) — Healthcare Realty Trust Incorporated (NYSE:HR) today announced the nomination of 11 of […]
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients Durability of clinical activity […]
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on […]
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
— Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ […]
